Fear of Childbirth and Its Association With Mode of Delivery, Labor Pain, and Epidural Analgesia Request in First-Time Mothers (FOC-LABOR)

November 12, 2026 updated by: Ayşenur Türe, Ankara City Hospital Bilkent

Association of Fear of Childbirth Level, Measured by the Wijma Delivery Expectancy/Experience Questionnaire Version A (W-DEQ-A), With Mode of Delivery, Labor Pain, and Epidural Analgesia Request in Nulliparous Term Pregnant Women: A Prospective Observational Study

The goal of this observational study is to learn whether the level of fear of childbirth before active labor is related to how the baby is born, how intense labor pain is, and whether epidural pain relief is requested, in first-time mothers with a full-term pregnancy who plan a vaginal birth.

The main questions it aims to answer are:

  • Do women with severe fear of childbirth have a higher rate of unplanned (emergency) cesarean delivery?
  • Do women with more fear of childbirth feel more intense labor pain?
  • Do women with more fear of childbirth ask for an epidural more often, and earlier in labor?

Researchers will compare women with severe fear of childbirth (a score of 85 or higher on the Wijma Delivery Expectancy/Experience Questionnaire, version A, or W-DEQ-A) with women whose scores are below 85.

Participants will:

  • Fill out the Turkish version of the W-DEQ-A, a 33-item questionnaire about thoughts and feelings regarding the coming birth. It is completed once after admission to the labor ward, before active labor and before any pain relief, and takes about 10 to 15 minutes.
  • Rate their labor pain on a scale from 0 (no pain) to 10 (worst imaginable pain) during active labor and, if they ask for an epidural, at the time of the request.
  • Receive routine labor care. The study does not change any treatment or clinical decision; information on labor, pain relief and delivery will be collected from hospital records.

The study will take place at Ankara Bilkent City Hospital in Ankara, Türkiye.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

BACKGROUND

Fear of childbirth (FOC) is common in pregnancy. A systematic review and meta-analysis of 29 studies including 853,988 pregnant women estimated the worldwide pooled prevalence of tocophobia at 14% (95% confidence interval 12-16%). Previous studies have linked FOC to requests for cesarean delivery without a medical indication, longer labor, greater use of epidural analgesia and a more negative birth experience. Evidence on whether fear measured before active labor predicts intrapartum outcomes in nulliparous women who plan a vaginal birth is inconsistent, and prospective data from Türkiye, which has the highest cesarean delivery rate among OECD countries, are limited.

The Wijma Delivery Expectancy/Experience Questionnaire (W-DEQ) is the most widely used instrument for measuring FOC. Version A (W-DEQ-A) assesses a woman's expectations of the coming birth during pregnancy. It consists of 33 items rated on a 6-point Likert scale (0-5), giving a total score from 0 to 165; higher scores indicate greater fear, and a score of 85 or higher is commonly used to define severe FOC. The Turkish version of the W-DEQ-A has been validated in pregnant women (Cronbach's alpha 0.89).

OBJECTIVES

Primary objective: to determine whether severe FOC (W-DEQ-A score of 85 or higher), measured before active labor, is associated with intrapartum (unplanned) cesarean delivery in nulliparous women with a term singleton pregnancy who plan a vaginal birth.

Secondary objectives: to assess the association of FOC, analyzed both as a continuous W-DEQ-A score and as a dichotomous group, with (1) mode of delivery, (2) labor pain intensity, and (3) the request for epidural labor analgesia and the cervical dilatation at which it is requested.

Exploratory objectives: to describe the duration of the active first stage and second stage of labor and the indications for intrapartum cesarean delivery according to FOC level.

DESIGN AND SETTING

This is a single-center, prospective observational cohort study conducted in the labor and delivery unit of the Department of Obstetrics and Gynecology, Ankara Bilkent City Hospital, a tertiary referral center in Ankara, Türkiye. The investigators do not assign any intervention. Labor management, induction, analgesia and decisions on operative delivery follow routine institutional practice and are made by the attending clinical team. W-DEQ-A scores will not be shared with the team managing labor, so that clinical decisions are not influenced by the study.

PARTICIPANTS AND PROCEDURES

Nulliparous women aged 18 to 45 years with a singleton, cephalic, term pregnancy (37+0 to 41+6 weeks) who are admitted for planned vaginal birth, either in the latent phase of spontaneous labor or for induction of labor, will be screened consecutively. After written informed consent, and before active labor (cervical dilatation less than 5 cm) and before any analgesia, participants will complete the Turkish W-DEQ-A in a quiet setting. Sociodemographic and obstetric characteristics will be recorded on a standardized data collection form that contains no names or national identity numbers. Labor, delivery and neonatal data will be collected prospectively by the research team and verified against medical records until discharge.

EXPOSURE

The exposure is the W-DEQ-A total score, analyzed as a continuous variable (per 10-point increase) and dichotomized at 85 (severe FOC versus non-severe FOC).

OUTCOME ASSESSMENT

  • Mode of delivery: spontaneous vaginal, operative vaginal (vacuum or forceps) or intrapartum cesarean delivery, with the primary indication for cesarean delivery.
  • Labor pain: 10-cm visual analogue scale (VAS; 0 = no pain, 10 = worst imaginable pain) at the first vaginal examination showing cervical dilatation of 5 cm or more before any analgesia, and at the time of an epidural request before the block is placed.
  • Epidural analgesia: whether the participant requests epidural analgesia, the time and cervical dilatation at the request, and whether the epidural is placed.
  • Labor characteristics: onset of labor (spontaneous or induced), oxytocin augmentation, duration of the active first stage and second stage of labor, birth weight and Apgar scores.

COVARIATES

Prespecified potential confounders are maternal age, body mass index, education level, gestational age, attendance at antenatal education classes, onset of labor (spontaneous or induced) and birth weight. Epidural analgesia and oxytocin augmentation lie on the possible causal pathway between FOC and mode of delivery; they will be examined as mediators in sensitivity analyses rather than adjusted for in the main model.

SAMPLE SIZE

Assuming an intrapartum cesarean rate of 25% among women with a W-DEQ-A score below 85 and a 20% prevalence of severe FOC (group ratio 1:4), 460 women (92 with severe FOC and 368 without) are needed to detect an increase in the cesarean rate to 40% (relative risk 1.6; odds ratio 2.0) with 80% power and a two-sided alpha of 0.05. To allow for about 10% incomplete data or protocol deviations, 512 women will be enrolled.

STATISTICAL ANALYSIS

Continuous variables will be summarized as mean (standard deviation) or median (interquartile range) and compared with the t-test or Mann-Whitney U test; categorical variables will be compared with the chi-square or Fisher's exact test. Multivariable logistic regression will estimate the association of FOC with intrapartum cesarean delivery and with epidural request, reported as adjusted odds ratios with 95% confidence intervals. Linear regression will be used for VAS scores and for cervical dilatation at epidural request. The ability of the W-DEQ-A score to discriminate women who undergo intrapartum cesarean delivery will be explored with receiver operating characteristic (ROC) analysis. A two-sided p value below 0.05 will be considered statistically significant.

ETHICS AND DATA PROTECTION

The study will start only after approval by the Ankara Bilkent City Hospital Medical Research Scientific and Ethical Evaluation Board (TABED). Written informed consent will be obtained from all participants, who may withdraw at any time without any effect on their care. The study will be conducted in accordance with the Declaration of Helsinki (2024 revision) and Good Clinical Practice, and personal data will be processed in line with the Turkish Personal Data Protection Law (KVKK, Law No. 6698).

Study Type

Observational

Enrollment (Estimated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Nulliparous women aged 18 to 45 years with a singleton, cephalic, term pregnancy (37+0 to 41+6 weeks) who are admitted to the labor and delivery unit of Ankara Bilkent City Hospital, a tertiary referral center in Ankara, Türkiye, for planned vaginal birth, either in the latent phase of spontaneous labor or for induction of labor. Eligible women will be invited consecutively during the recruitment period.

Description

Inclusion Criteria:

  • Nulliparous women (no previous birth at 20 weeks of gestation or later)
  • Age 18 to 45 years
  • Singleton pregnancy in cephalic presentation
  • Term gestation of 37+0 to 41+6 weeks, dated by first-trimester ultrasound or a reliable last menstrual period
  • Admission to the labor and delivery unit for planned vaginal birth, either in the latent phase of spontaneous labor (cervical dilatation less than 5 cm) or for induction of labor
  • Able to read and understand Turkish
  • Written informed consent

Exclusion Criteria:

  • Planned cesarean delivery or a contraindication to vaginal birth (for example placenta previa or previous uterine surgery entering the uterine cavity)
  • Cervical dilatation of 5 cm or more at enrollment
  • Any analgesic given for labor pain before the questionnaire is completed
  • Contraindication to neuraxial (epidural) analgesia, such as coagulopathy, significant thrombocytopenia or infection at the puncture site
  • Known major fetal anomaly or intrauterine fetal death
  • Severe maternal disease likely to change labor or analgesia management, such as preeclampsia with severe features or significant heart disease
  • Psychiatric disorder requiring medication, or current use of psychotropic drugs
  • Inability to complete the questionnaire, for example because of cognitive impairment or a language barrier

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Severe Fear of Childbirth (W-DEQ-A Score 85 or Higher)

Nulliparous women with a term singleton pregnancy planning vaginal birth whose W-DEQ-A total score at enrollment is 85 or higher, indicating severe fear of childbirth. Participants receive routine labor care; no intervention is assigned by the investigators.

Self-administered Turkish version of the W-DEQ-A: 33 items rated on a 6-point Likert scale (total score 0-165; higher scores indicate greater fear of childbirth), completed once at enrollment before active labor and before any analgesia. It is used only to measure fear of childbirth and does not change clinical care.

Non-severe Fear of Childbirth (W-DEQ-A Score Below 85)

Nulliparous women with a term singleton pregnancy planning vaginal birth whose W-DEQ-A total score at enrollment is below 85. Participants receive routine labor care; no intervention is assigned by the investigators.

Self-administered Turkish version of the W-DEQ-A: 33 items rated on a 6-point Likert scale (total score 0-165; higher scores indicate greater fear of childbirth), completed once at enrollment before active labor and before any analgesia. It is used only to measure fear of childbirth and does not change clinical care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of Intrapartum (Unplanned) Cesarean Delivery
Time Frame: From enrollment to delivery during the same hospital admission (up to 7 days)

Percentage of participants delivered by intrapartum (unplanned) cesarean section, compared between participants with a W-DEQ-A score of 85 or higher and those with a score below 85. The W-DEQ-A total score ranges from 0 to 165, with higher scores indicating greater fear of childbirth; the association with the continuous score will also be assessed.

From enrollment to delivery during the same hospital admission (up to 7 days)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mode of Delivery
Time Frame: At delivery (up to 7 days after enrollment)

Number and percentage of participants with spontaneous vaginal delivery, operative vaginal delivery (vacuum or forceps) and intrapartum cesarean delivery, compared between the two W-DEQ-A groups.

At delivery (up to 7 days after enrollment)
Rate of Epidural Analgesia Request
Time Frame: From enrollment to delivery (up to 7 days)

Percentage of participants who request epidural analgesia during labor, as documented by the attending midwife or physician, regardless of whether the epidural is placed.

From enrollment to delivery (up to 7 days)
Cervical Dilatation at the Time of Epidural Request
Time Frame: At the time of epidural request (during labor)

Cervical dilatation in centimeters (0-10 cm) at the vaginal examination performed at the time of the epidural request, among participants who request epidural analgesia. Lower values indicate an earlier request in labor.

At the time of epidural request (during labor)
Labor Pain Intensity in Active Labor
Time Frame: At the first vaginal examination showing cervical dilatation of 5 cm or more (active phase of labor)

Pain intensity measured with a 10-cm visual analogue scale (VAS; 0 = no pain, 10 = worst imaginable pain; higher scores indicate more pain) at the first vaginal examination showing cervical dilatation of 5 cm or more, before any analgesia.

At the first vaginal examination showing cervical dilatation of 5 cm or more (active phase of labor)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: AYŞENUR TÜRE, ANKARA BİLKENT CİTY HOSPİTAL

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2026

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

January 31, 2027

Study Registration Dates

First Submitted

November 12, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • TABED 2-26-2777

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared, in accordance with the Turkish Personal Data Protection Law (KVKK, Law No. 6698), the informed consent obtained from participants and the institutional data-use commitment of Ankara Bilkent City Hospital. Aggregated results will be published in a peer-reviewed journal.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.